Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6-7
pubmed:dateCreated
1999-6-5
pubmed:abstractText
Space motion sickness has been estimated as affecting between 1/3 and 1/2 of all space flight participants. NASA has at the moment proposed a combination of promethazine and ephedrine (P/E) and one of scopolamine and dextroamphetamine (S/D), both given orally, as well as a transdermally applied scopolamine (TAS), as preventive and ameliorative measures. The reported double-blind study, tests the early phase actions and efficacy of the transdermal scopolamine (Transderm (TM)-V of ALZA Corporation) and compares these in detail to the oral medications. Motion sickness resistance was tested by standardized head movements while accelerating at 0.2 degree/sec2 to a maximum rotation of 240 degrees/sec, with an intermediate plateau of 10 min at 180 degrees/sec. To permit weighting motion sickness protection against other system influences, cardiovascular, psychological (subjective and objective), and visual parameter changes were documented for the three therapeutic modes. The relative impact of the various modalities on operational and experimental components of space missions is discussed. A comparison to intramuscularly administered promethazine (a backup therapeutic mode suggested for Space Shuttle use) is also included.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
S
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0094-5765
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NASA
pubmed:authorsComplete
Y
pubmed:pagination
375-83
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:11541691-Administration, Cutaneous, pubmed-meshheading:11541691-Administration, Oral, pubmed-meshheading:11541691-Adult, pubmed-meshheading:11541691-Aerospace Medicine, pubmed-meshheading:11541691-Antiemetics, pubmed-meshheading:11541691-Central Nervous System Stimulants, pubmed-meshheading:11541691-Dextroamphetamine, pubmed-meshheading:11541691-Double-Blind Method, pubmed-meshheading:11541691-Drug Evaluation, pubmed-meshheading:11541691-Drug Therapy, Combination, pubmed-meshheading:11541691-Ephedrine, pubmed-meshheading:11541691-Head Movements, pubmed-meshheading:11541691-Hemodynamics, pubmed-meshheading:11541691-Humans, pubmed-meshheading:11541691-Injections, Intramuscular, pubmed-meshheading:11541691-Male, pubmed-meshheading:11541691-Promethazine, pubmed-meshheading:11541691-Psychological Tests, pubmed-meshheading:11541691-Rotation, pubmed-meshheading:11541691-Scopolamine Hydrobromide, pubmed-meshheading:11541691-Space Motion Sickness, pubmed-meshheading:11541691-Weightlessness Countermeasures
pubmed:articleTitle
Relative efficacy of the proposed Space Shuttle antimotion sickness medications.
pubmed:affiliation
DFVLR-Institute for Aerospace Medicine, Koln, FRG.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial